Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients

In by Hannah Schaffner

Locations
Jacksonville - Florida Eye Specialist (Gate)
Condition
Ocular Hypertension, Open-Angle Glaucoma

Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients

  • Hidden
  • This field is for validation purposes and should be left unchanged.

The main study purpose is to demonstrate the non-inferiority of T4032 compared to Lumigan® 0.01% in terms of efficacy.

clinicaltrials.gov

Eligibility

Inclusion Criteria
  1. Informed consent dated and signed.
  2. Both eyes diagnosed open-angle glaucoma or ocular hypertension
Exclusion Criteria
  1. History of trauma, infection, clinically significant inflammation within the previous 3 months
  2. Known or suspected hypersensitivity to one of the components of the Investigational Medicinal Product(s)
  3. Pregnancy or breast-feeding
Back to Current Studies